DE69731084D1 - REINIGUNG DES GEWEBE PLASMINOGENAKTIVATORS (tPA) - Google Patents

REINIGUNG DES GEWEBE PLASMINOGENAKTIVATORS (tPA)

Info

Publication number
DE69731084D1
DE69731084D1 DE69731084T DE69731084T DE69731084D1 DE 69731084 D1 DE69731084 D1 DE 69731084D1 DE 69731084 T DE69731084 T DE 69731084T DE 69731084 T DE69731084 T DE 69731084T DE 69731084 D1 DE69731084 D1 DE 69731084D1
Authority
DE
Germany
Prior art keywords
target
binding
ligands
release
preselected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69731084T
Other languages
English (en)
Other versions
DE69731084T2 (de
Inventor
M Maclennan
C Ladner
C Ransohoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Application granted granted Critical
Publication of DE69731084D1 publication Critical patent/DE69731084D1/de
Publication of DE69731084T2 publication Critical patent/DE69731084T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DE69731084T 1996-03-20 1997-03-20 REINIGUNG DES GEWEBE PLASMINOGENAKTIVATORS (tPA) Expired - Lifetime DE69731084T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61988596A 1996-03-20 1996-03-20
US619885 1996-03-20
PCT/US1997/004426 WO1997035197A1 (en) 1996-03-20 1997-03-20 PURIFICATION OF TISSUE PLASMINOGEN ACTIVATOR (tPA)

Publications (2)

Publication Number Publication Date
DE69731084D1 true DE69731084D1 (de) 2004-11-11
DE69731084T2 DE69731084T2 (de) 2006-02-23

Family

ID=24483730

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69731084T Expired - Lifetime DE69731084T2 (de) 1996-03-20 1997-03-20 REINIGUNG DES GEWEBE PLASMINOGENAKTIVATORS (tPA)

Country Status (12)

Country Link
US (3) US6084062A (de)
EP (3) EP0907887A4 (de)
JP (2) JP2000510443A (de)
CN (1) CN1198837C (de)
AT (1) ATE278958T1 (de)
AU (2) AU715608B2 (de)
CA (1) CA2248243C (de)
DE (1) DE69731084T2 (de)
ES (1) ES2229347T3 (de)
IL (2) IL126044A (de)
PT (1) PT904541E (de)
WO (2) WO1997035197A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0564531B1 (de) * 1990-12-03 1998-03-25 Genentech, Inc. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
EP0907887A4 (de) * 1996-03-20 2002-10-30 Dyax Corp Durch genmanipulation erhaltene affinitätsliganden für makromoleküle
AU5122499A (en) 1998-07-27 2000-02-21 Genentech Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6197526B1 (en) * 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
DE60029029T2 (de) * 1999-03-26 2007-06-14 City Of Hope, Duarte Screenen nach FXR-Rezeptormodulatoren
US6733451B2 (en) 1999-10-05 2004-05-11 Omnisonics Medical Technologies, Inc. Apparatus and method for an ultrasonic probe used with a pharmacological agent
US20040097996A1 (en) 1999-10-05 2004-05-20 Omnisonics Medical Technologies, Inc. Apparatus and method of removing occlusions using an ultrasonic medical device operating in a transverse mode
GB0002660D0 (en) * 2000-02-04 2000-03-29 Biomade B V Method of stabilizing a hydrophobin-containing solution and a method of coatinga surface with a hydrophobin
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
ES2317924T3 (es) 2000-07-27 2009-05-01 Genentech, Inc. Administracion secuencial de cpt-11 y polipeptido apo-2l.
JP5109003B2 (ja) * 2000-10-13 2012-12-26 岡野 光夫 刺激応答型アフィニティクロマトグラフィー材料等の分離材料および分離精製方法
AU2002303384A1 (en) 2001-04-17 2002-10-28 William J. Dower Epitope-captured antibody display
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
WO2003000113A2 (en) 2001-06-20 2003-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ556415A (en) 2002-01-02 2009-02-28 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
NZ544317A (en) 2003-07-08 2009-05-31 Genentech Inc IL-17 A/F heterologous polypeptides and therapeutic uses thereof
CA2747871C (en) 2003-11-17 2018-04-10 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7794414B2 (en) 2004-02-09 2010-09-14 Emigrant Bank, N.A. Apparatus and method for an ultrasonic medical device operating in torsional and transverse modes
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN101175769A (zh) 2005-03-10 2008-05-07 健泰科生物技术公司 用于调控血管完整性的方法和组合物
EP2614839A3 (de) 2006-04-05 2015-01-28 Genentech, Inc. Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
AU2007284651B2 (en) 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008032833A1 (fr) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Anticorps présentant une activité adcc accrue et son procédé de production
JP5761915B2 (ja) 2007-02-22 2015-08-12 ジェネンテック， インコーポレイテッド 炎症性腸疾患の検出方法
CA2728473A1 (en) 2008-06-20 2009-12-23 National University Corporation Okayama University Antibody against oxidized ldl/.beta.2gpi complex and use of the same
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
MX2012006072A (es) 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
BR112012028010A2 (pt) 2010-05-03 2017-09-26 Genentech Inc anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
US9428789B2 (en) 2011-03-21 2016-08-30 Biodesy, Inc. Classification of kinase inhibitors using nonlinear optical techniques
EP2756300A1 (de) 2011-09-15 2014-07-23 F.Hoffmann-La Roche Ag Verfahren zur förderung der differenzierung
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
MX2014008699A (es) 2012-01-18 2014-11-21 Genentech Inc Metodos para utilizar moduladores de fgf19.
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
JP2015511598A (ja) 2012-03-16 2015-04-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐａｋ１阻害剤を用いて黒色腫を治療する方法
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
MX2014010943A (es) 2012-03-16 2014-11-26 Genentech Inc Proteinas estabilizadas conformacionalmente de ingenieria.
EP2841951B1 (de) 2012-04-25 2019-12-11 Biodesy, Inc. Verfahren zum nachweis von allosterischen proteinmodulatoren
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP3633377A1 (de) 2013-03-15 2020-04-08 F. Hoffmann-La Roche AG Biomarker und verfahren zur behandlung von pd-1 und pd-l1-verwandten leiden
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
CA2944717A1 (en) 2014-05-23 2015-11-26 Genentech, Inc. Mit biomarkers and methods using the same
WO2015196070A1 (en) 2014-06-20 2015-12-23 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
EP3237906B8 (de) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
JP2019534858A (ja) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
FR3056753B1 (fr) 2016-09-23 2021-01-01 Plant Advanced Tech Pat Procede de determination de l’affinite entre des ligands et une cible
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP4230649A3 (de) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein barr-virusinfektion
EP3655430A1 (de) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose und behandlung von hepatitis-b-virusinfektionen
BR112021008878A2 (pt) * 2018-11-08 2021-08-31 Unilever Ip Holdings B.V. Método de tratamento de uma superfície e uso de uma lactama
CN109580818B (zh) * 2018-12-14 2022-04-08 江西省农业科学院农产品质量安全与标准研究所 一种检测猪毛发中氟苯尼考药物残留量的方法
AR122263A1 (es) 2019-05-09 2022-08-31 Genentech Inc Métodos para producir anticuerpos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3382389D1 (de) * 1982-12-14 1991-10-02 South African Inventions Plasminogenaktivator.
JPS6119485A (ja) * 1984-07-06 1986-01-28 Nippon Kayaku Co Ltd プロテア−ゼ吸着体
US4898825A (en) * 1986-05-07 1990-02-06 Mitsui Toatsu Chemicals, Incorporated Methods for purification of single-chain and double-chain tissue plasminogen activator
US5133866A (en) * 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
CA1341598C (en) * 1988-07-15 2009-09-29 Central Sydney Area Health Service Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
US5227297A (en) * 1990-04-17 1993-07-13 Smithkline Beecham Corporation Affinity purification ligands
US5141862A (en) * 1990-04-17 1992-08-25 Smithkline Beecham Corporation Method of purifying tpa or plasminogen activator using a tripeptide of the formula: -X-Y-argininal wherein X and Y are selected from the group consisting of pro,phe,trp and tyr
JP2661790B2 (ja) * 1990-11-27 1997-10-08 電気化学工業株式会社 入尿トリプシンインヒビターの精製方法
EP0907887A4 (de) * 1996-03-20 2002-10-30 Dyax Corp Durch genmanipulation erhaltene affinitätsliganden für makromoleküle

Also Published As

Publication number Publication date
IL126045A0 (en) 1999-05-09
ATE278958T1 (de) 2004-10-15
IL126044A0 (en) 1999-05-09
AU2658397A (en) 1997-10-10
CA2248243A1 (en) 1997-09-25
ES2229347T3 (es) 2005-04-16
JPH11507246A (ja) 1999-06-29
DE69731084T2 (de) 2006-02-23
EP0907887A1 (de) 1999-04-14
WO1997035197A1 (en) 1997-09-25
IL126044A (en) 2006-08-01
US6462172B1 (en) 2002-10-08
CA2248243C (en) 2010-05-25
EP0904541B1 (de) 2004-10-06
US7074560B2 (en) 2006-07-11
CN1219240A (zh) 1999-06-09
AU715608B2 (en) 2000-02-03
US20030162942A1 (en) 2003-08-28
EP0907887A4 (de) 2002-10-30
EP0904541A4 (de) 2000-07-26
US6084062A (en) 2000-07-04
EP0904541A1 (de) 1999-03-31
JP2000510443A (ja) 2000-08-15
AU713744B2 (en) 1999-12-09
CN1198837C (zh) 2005-04-27
PT904541E (pt) 2005-01-31
WO1997035196A1 (en) 1997-09-25
AU2535697A (en) 1997-10-10
EP1944610A1 (de) 2008-07-16

Similar Documents

Publication Publication Date Title
DE69731084D1 (de) REINIGUNG DES GEWEBE PLASMINOGENAKTIVATORS (tPA)
ATE398179T1 (de) Von rna polymerasen abstammende polypeptide und ihre verwendungen
DE60333963D1 (de) Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität
DK0542770T3 (da) Randomiseret bio-oligomer-bibliotek, en fremgangsmåde til syntese deraf og en fremgangsmåde til anvendelse deraf
ATE283635T1 (de) Verfahren zur herstellung von geschmacksfreiem hochreinem rauch zur behandlung von zum einfrieren und auftauen vorgesehenen meeresprodukten
PL374311A1 (en) Methods for purifying protein
ATE397092T1 (de) Methode zur direkten sequenzierung von nukleinsäuren
IL193886A0 (en) Antibodies that bind to ldcam sequences
ATE554165T1 (de) Stabilisierung von nukleinsäuren
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE449104T1 (de) Verfahren zur reinigung von fibrinogen
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE69534551D1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
KUMAZAKI et al. Affinity chromatography on immobilized anhydrotrypsin: general utility for selective isolation of C-terminal peptides from protease digests of proteins
ATE380827T1 (de) Verfahren zur chromatographischen reinigung von insulinen
DE60233202D1 (de) Verfahren zur extrahierung, fraktionierung und reinigung mittels eines harzes mit hohem adsorptions- und eluierungsrendement, von polyphenolischen verbindungen erhalten aus ausleseabfällen von frischen gemüsen
ATE333469T1 (de) Verfahren zur reinigung hochanionischer proteine
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
ATE215964T1 (de) Phrothrombin und thrombin bindende peptide.
DE60029429D1 (de) Verfahren und zusammensetzungen zur überwachung der modifikation von natürlichen bindungspartners
ATE431408T1 (de) Methode zur trennung und aufreinigung von nukleinsäuren
CA2245675A1 (en) Engineering affinity ligands for macromolecules
Liu et al. Synthesis of a precursor of bioactive pentapeptide OGP-(10-14) and the fragment of enkephalin catalyzed by MCM-22 immobilized or free proteases in organic solvents
WO2004007536A3 (en) Interactions of the epstein-barr virus protein ebna1, and uses thereof
HUT71326A (en) Purification of kringle containing proteins, and especially t-pa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition